Basic Information
| LncRNA/CircRNA Name | THAP9-AS1 |
| Synonyms | THAP9 antisense RNA 1 |
| Region | GRCh38_4:82893009-82900960 |
| Ensemble | ENSG00000251022 |
| Refseq | NR_034075 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | RIP, qRT-PCR |
| Sample | Pancreatic ductal adenocarcinoma cell lines PANC-1, SW1990, CFPAC-1 and BxPc-3, and HEK293T cells,PDAC and non-cancerous tissues |
| Expression Pattern | up-regulated |
| Function Description | lncRNA THAP9-AS1 is overexpressed in PDAC in multiple patient sample sets, which is significantly associated with poor outcome of patients with PDAC. THAP9-AS1 promotes PDAC cells growth both in vitro and in vivo. THAP9-AS1 exerts its effects via enhancing YAP signaling.THAP9-AS1 acts as a competing endogenous RNA for miR-484, leading to YAP upregulation. |
| Pubmed ID | 31831555 |
| Year | 2020 |
| Title | lncRNA THAP9-AS1 Promotes Pancreatic Ductal Adenocarcinoma Growth and Leads to a Poor Clinical Outcome via Sponging miR-484 and Interacting With YAP |
External Links
| Links for THAP9-AS1 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |